Konrad Turczynowski

Konrad Turczynowski

Auto-generated profile, based on publicly available information

Konrad Turczynowski

University Hospital in Kraków Jakubowskiego 2, 30-688 Kraków

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
JLJakub Michał Lichoń
Jakub Michał Lichoń
PKPaweł Jan Kuna
Paweł Jan Kuna
WKWojciech Kuna
Wojciech Kuna
JPJakub Mateusz Pietrucha
Jakub Mateusz Pietrucha
KTKamil Igor Turczynowski
Kamil Igor Turczynowski
KTKonrad Olaf Turczynowski
Konrad Olaf Turczynowski
The dynamic advancements in artificial intelligence are enabling the integration of machine learning into medical practice. A significant challenge in modern anesthesiology is the need for precise, continuous adjustment of anesthetic drug doses in response to the patient's rapidly changing physiological state. Traditional manual methods of drug delivery often result in excessive variability in the depth of anesthesia and hemodynamic stability. Utilizing machine learning algorithms represents a modern, promising approach designed to enhance the overall quality and safety of anesthetic care. Aim of the study: The objective of this study is to review the current state of knowledge concerning machine algorithms in automated anesthetic drug delivery systems and to compare these with conventional administration methods, evaluating the benefits and limitations of each approach. Materials and methods: A review of selected literature in the PubMed, Google Scholar database was conducted, using the following keywords: “anesthetic drugs”, “machine learning”, “closed-loop system” “artificial intelligence” Conclusions: The review demonstrates that Machine Learning-driven Closed-Loop Anesthesia Delivery Systems (CLADS) offer superior stability of anesthetic depth and hemodynamic control compared to manual administration. The implementation of AI allows for the personalization of therapy and a significant reduction in drug and gas wastage, supporting the "Green Anesthesia" initiative. Furthermore, automation contributes to better long-term outcomes, such as reduced incidence of postoperative delirium and cognitive dysfunction. However, despite high autonomy, the "human-in-the-loop" paradigm remains essential due to technical artifacts and unforeseen surgical events. Future research should focus on regulatory standardization and the integration of multi-loop systems managing hypnosis, analgesia, and neuromuscular blockade simultaneously.

18 January 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
PKPaweł Jan Kuna
Paweł Jan Kuna
MGMateusz Gołdyn
Mateusz Gołdyn
KTKonrad Turczynowski
Konrad Turczynowski
JPJakub Pietrucha
Jakub Pietrucha
JLJakub Lichoń
Jakub Lichoń
WHWiktoria Haberko
Wiktoria Haberko
Introduction: Parkinson’s Disease (PD) and Essential Tremor (ET) are the two most prevalent movement disorders, with tremor being a core, often drug-refractory, motor feature. While traditional surgical treatments like Deep Brain Stimulation (DBS) and Radiofrequency (RF) ablation are effective, they are invasive and carry inherent risks such as hemorrhage and infection, necessitating craniotomy. This reality drives the need for less invasive therapeutic options for patients with advanced, medication-refractory symptoms and motor fluctuations. Aim: The aim of this systematic review is to assess the clinical efficacy and safety profile of Thalamotomy and Pallidotomy performed using Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) technology in the treatment of Essential Tremor and Parkinson’s Disease. Review methods: A comprehensive analysis of research papers available on PubMed and Google Scholar was conducted using keywords: Focused Ultrasound (FUS), Essential Tremor (ET), Parkinson's Disease (PD), Thalamotomy, Pallidotomy, MRgFUS. Conclusion: MRgFUS-guided thalamotomy (VIM) and pallidotomy (GPi) constitute a breakthrough, non-invasive alternative to traditional surgical ablations. The technology demonstrates high and durable efficacy, achieving a 47% reduction in ET tremor and a 39,1% reduction in PD motor symptoms (UPDRS III), comparable to invasive standards. Crucially, MRgFUS offers a favorable safety profile by eliminating the risk of surgical bleeding and infection while providing real-time lesion monitoring. However, a key limitation remains the requirement for an adequate Skull Density Ratio (SDR), excluding some clinically eligible patients. Further long-term, prospective studies are required to fully establish its role.

18 January 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
WKWojciech Kuna
Wojciech Kuna
JNJakub Niski
Jakub Niski
JPJakub Mateusz Pietrucha
Jakub Mateusz Pietrucha
ARAnna Rutkowska
Anna Rutkowska
JLJakub Michał Lichoń
Jakub Michał Lichoń
KTKonrad Olaf Turczynowski
Konrad Olaf Turczynowski
Drug-resistant epilepsy (DRE) is a neurological condition, defined as a failure to make the patient seizure free, after the use of two tolerated, appropriately chosen antiepileptic drugs (AED). Although there is an increasing number of available antiepileptic drugs, it is estimated that pharmacotherapy remains ineffective in approximately 30% of patients. Drug-resistant epilepsy is considered as one of the greatest challenges in modern neurology that affects millions of patients worldwide, who do not respond to standard treatments. Even though epilepsy is one of the most common neurological diseases, with a global total of 50 million people suffering from the condition, treatment of its resistant forms remains complicated and often ineffective. Chronic epileptic seizures can cause serious health problems, limiting patients' mobility, affecting quality of life and increasing the risk of emotional disorders such as depression and anxiety. In response to this challenge, the development of modern drugs for drug-resistant epilepsy has become a medical priority. In recent years, there has been growing interest in new medications such as Cenobamate, Fenfluramine and Cannabidiol, which have different mechanisms of action and promising results in reducing the seizure frequency. Before diagnosing DRE, it is essential to exclude the pseudo-resistance, which may result from different factors such as inadequate doses of medicine, choosing the incorrect medications, or patient-related errors (poor compliance).

17 February 2026 in Quality in Sport
Verified
Journal Article
Open access
KTKonrad Turczynowski
Konrad Turczynowski
JLJakub Lichoń
Jakub Lichoń
PKPaweł Kuna
Paweł Kuna
WKWojciech Kuna
Wojciech Kuna
JPJakub Pietrucha
Jakub Pietrucha
DSDawid Studziński
Dawid Studziński
Background.GLP-1 receptor agonists (GLP-1RAs) are central to obesity pharmacotherapy, producing substantial and sustained weight loss in randomized trials, with additional cardiometabolic benefits. Growing attention concerns their effects on body composition, particularly fat versus lean mass loss, and potential impacts on skeletal muscle function and physical performance. These outcomes are highly relevant to sports medicine and rehabilitation, where muscle preservation is crucial. Aim.To review evidence on the effects of GLP-1RAs on body composition and physical performance in adults with obesity, focusing on fat mass, lean mass and populations at risk of muscle-related adverse effects. Materials and methods.Narrative review of 30 PubMed-indexed studies (2015–2026), including RCTs, DXA substudies and reviews of liraglutide, semaglutide and tirzepatide in adults with overweight/obesity. Results.GLP-1RAs consistently reduced body weight and fat mass, with 15–40% of weight loss attributable to lean mass reduction. Semaglutide improved physical function and exercise tolerance in obesity-related functional impairment and HFpEF, while potential sarcopenic effects were reported in older adults and those with low baseline muscle mass. Reviews highlight heterogeneity of lean mass responses and the importance of lifestyle interventions. Conclusions.GLP-1RAs induce major fat loss but are associated with clinically relevant lean mass loss. Combining pharmacotherapy with exercise and nutrition is essential to optimize body composition and physical performance.

12 March 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
KTKonrad Turczynowski
Konrad Turczynowski
JLJakub Lichoń
Jakub Lichoń
ZŁZuzanna Łyko
Zuzanna Łyko
WKWojciech Kuna
Wojciech Kuna
JPJakub Pietrucha
Jakub Pietrucha
DSDawid Studziński
Dawid Studziński
Background. Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are widely used in the treatment of type 2 diabetes mellitus, chronic kidney disease, and heart failure. Although these agents promote weight loss and improve cardiometabolic outcomes, concerns have emerged regarding potential reductions in skeletal muscle mass and their impact on physical function. Aim. To review current evidence on the effects of SGLT2 inhibitors on skeletal muscle mass, muscle strength, and functional outcomes. Material and methods. A systematic narrative review of English-language studies published between 2020 and 2026 was conducted. Randomized controlled trials, observational studies, and meta-analyses evaluating body composition and functional performance outcomes during SGLT2 inhibitor therapy were included. Results. SGLT2 inhibitors consistently reduced body weight primarily through fat mass loss, while reductions in lean mass were generally small. Skeletal muscle mass and handgrip strength were largely preserved in middle-aged adults, whereas greater variability was observed in older individuals and patients with chronic kidney disease. Evidence suggests that physical activity and adequate nutrition may mitigate potential muscle loss. Conclusions. SGLT2 inhibitors promote favorable body recomposition with predominantly fat mass reduction and minimal effects on muscle function in most patients. Monitoring muscle health and supporting lifestyle interventions may be beneficial in vulnerable populations.

24 May 2026 in Quality in Sport
Verified
Journal Article
Open access
DSDawid Studziński
Dawid Studziński
WSWiktoria Szkatuła
Wiktoria Szkatuła
KOKarolina Osińska
Karolina Osińska
AKAnna Kołcz
Anna Kołcz
MKMichał Kulczak
Michał Kulczak
IOIzabela Ochońska
Izabela Ochońska
This systematic review formulates an organizational service framework integrating clinical urological data with sports management practices to mitigate disease-induced dropout among aging male athletes. Following PRISMA guidelines, a systematic search of PubMed (2021–2026) yielded 22 primary open-access articles evaluating physical activity, sedentary behaviors, and male urological or renal outcomes. High-volume cohort data confirms a robust inverse relationship between regular physical activity and the severity of lower urinary tract symptoms and erectile dysfunction, though extreme training volumes display a non-linear risk threshold. In clinical rehabilitation phases, supervised technological exercises paired with behavioral compliance models significantly accelerate post-surgical continence recovery. Longitudinally, overactive bladder symptoms serve as independent predictors of upper-limb grip strength decline and physical frailty. Sports enterprises can optimize service quality and member retention by moving from generic configurations toward age-appropriate, urologically sustainable exercise designs. Practical administrative interventions include expanding facility restroom accessibility to reduce public anxiety and embedding non-invasive urological screening metrics into routine physical assessments to preserve lifelong functional longevity.